Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2022 - 12 - 16
点击次数: 0
Positions: Financial Advisory Partner
Company: Deloitte
个人简介:
Kenneth Law is a M&A Transaction Services partner with 15 years of professional experience servicing clients across many international territories. He has extensive experience in managing cross-border transactions and has led engagement teams across US, European and APAC countries (including providing M&A support on many inbound transactions into Mainland China).
发布时间: 2022 - 12 - 16
点击次数: 0
Positions: Managing Director
Company: Morningside Ventures
个人简介:
Lily Shen M.Sc., M.B.A.    Morningside Ventures   Managing DirectorLily joined Morningside in 2010 and serves as board directors in more than ten Morningside portfolio companies. She has worked in life science industry for 18 years with rich experience in investment management and new drug R&D management in China. Lily received her master degree in M.B.A from Fudan University and Biochemistry and Molecular Biology from Xi’an Jiaotong University.
发布时间: 2022 - 12 - 16
点击次数: 0
Positions: Partner
Company: Trinity Innovation (Beijing) Investment Management Co., Ltd
个人简介:
Trinity Innovation (Beijing) Investment Management Co., Ltd is an investment institution focusing on the field of biomedical innovation. Before starting the company, Dr. Yin Served as the managing director of SDIC Innovation Investment Management Co., Ltd., responsible for equity investment in the pharmaceutical and healthcare sector, such as Dizal, Ribo, Ascentage, CanSino, Bright-gene, Ribo and EpimAb. Dr. Yin Worked in both biotech and global multinational pharmaceutical companies Novartis,  responsible for innovative drug discovery and project management; Previous positions include Dean of the School of Pharmacy of Nankai University, Deputy Director of the State Key Laboratory of Medicinal Chemical Biology, and Executive Director of the Center for Basic Molecular Science of Tsinghua University. He has been employed as a member of several national industry and science and technology professional committees. Dr. Yin Zheng also served as the PWC Investment and M&A of Consulting Director, and carried out investment and M &A consulting business in the Biomedical Industry.Bachelor and Master degree from Nankai University; Ph.D. of Science, National University of Singapore.
发布时间: 2022 - 12 - 16
点击次数: 0
Positions: Chief Strategy and Financial Officer
Company: Brii Biosciences
个人简介:
Dr. Li is Chief Financial Officer at Brii Biosciences. He has more than 10 years of experience in investment banking, business development, legal transaction and biomedical research. Before joining Brii Bio, he was the CFO of Terns Biopharmaceuticals to develop and deploy financial and corporate strategies and budget. Prior to Terns, Dr. Li was the Executive Director of Healthcare Investment Banking at Goldman Sachs responsible for Asia ex-Japan investment banking and led many high-profile IPOs for biotechnology and other healthcare clients. Dr. Li also worked in MSD Asia Pacific Innovation Hub, overseeing business development and licensing transactions in the region. Before that Dr. Li worked at international law firms, Davis Polk and Ropes & Gray, advising clients on M&A and investment transactions. Earlier in his career, he conducted postdoctoral biomedical research as Salk Institute in Dr. Ronald Evans’s lab.Ankang Li received a Juris Doctor degree from the University of Chicago Law School, a Ph.D. degree in Biomedical Sciences from Baylor College of Medicine, a Master of Science degree in Biological Sciences from the National University of Singapore, and a Bachelor of Science degree in Biochemistry from Fudan University. He is also a chartered Financial Analyst (CFA).